PDC BIOLOGICAL HEALTH GROUP CORPORATION
140 – 11120 Horseshoe Way
Richmond, British Columbia, V7A 5H7
March 24, 2014
PDC ANNOUNCES PRIVATE PLACEMENT
VANCOUVER, B.C. – PDC Biological Health Group Corporation is pleased to announce that it has arranged a non‐brokered private placement financing for gross proceeds of $50,000 through the issuance of 250,000 units (each, a “Unit”) at a price of $0.20 per Unit (the “Financing”). Each Unit will consist of one common share of the Company and one‐half of one nontransferable share purchase warrant (a “Warrant”). Each whole Warrant will entitle the holder to purchase one additional common share of the Company for a period of two years from the closing date at an exercise price of $0.50 per common share for the first twelve months and at an exercise price of $0.80 per common share thereafter.
All the securities issued in connection with this Offering are subject to a hold period expiring on
July 25, 2014.
PDC’s primary product, the CRT 2000 Thermographic System, is a non‐invasive, radiation‐free,reproducible thermographic tool that measures the temperature of predetermined skin points and analyzes such data to provide a health care practitioner with information that may be indicative of irregular body function. The CRT 2000 Thermographic System is intended for use in preventive healthcare. The CRT 2000 Thermographic System is presently ready for sale; it has obtained the CE Safety Mark (TUV) the FDA premarket notification Class I (510(k)) and is certified as a Class II medical device by the Chinese health authority (SFDA).
For further information, please contact:
PDC Biological Health Group Corporation
Chief Executive Officer
The CSE does not accept responsibility for the adequacy or accuracy of this release